Updates are available Correction dated 2020-08-10

Article History

Received: 2 April 2020

Accepted: 29 June 2020

First Online: 13 July 2020

Change Date: 10 August 2020

Change Type: Correction

Change Details: An amendment to this paper has been published and can be accessed via the original article.

Ethical approval and consent to participate

: This study protocol was reviewed and approved by Chesapeake Institutional Review Board (Pro00021615).

: Written informed consent was obtained from all participants prior to data use. No patient-identifying information was collected.

: This study was funded by Otsuka Pharmaceutical Development and Commercialization Inc. (Princeton, NJ, USA) and H. Lundbeck A/S (Valby, Denmark). Rajiv Tandon has nothing to report. CW is employed by Otsuka and MG was employed by Otsuka at the time of study and manuscript drafting. SRM and LBD are employed by H.Lundbeck A/S. CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen-Cilag, Lundbeck, Otsuka, Roche, Sage, Servier, Shire, Schering-Plough, Sumitomo Dainippon Pharma, Sunovion, and Takeda. WRL CDB, HS, OC and JC are Evidera employees. Evidera received consulting fees to conduct this research. OA is a consultant for Janssen-Ortho (Johnson & Johnson); Otsuka; Lundbeck; Sumitomo Dainippon Pharma and Minerva Neurosciences Inc, has received research grants from Janssen-Ortho, Otsuka, Boehringer Ingelheim, Neurocrine Bioscience, Acadia, Syneurx and diaMentis, and has served as a speaker for Janssen-Ortho, Lundbeck, Mylan Pharmaceuticals; Otsuka, HLS Therapeutics and Novartis. DC has received grant monies for research from Eli Lilly, Janssen Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca, Hospira; Travel Support and Honoraria for Talks and Consultancy from Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Lundbeck, Janssen Cilag,Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira, Servier, Seqirus; and is a current Advisory Board Member for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Aripiprazole LAI: Lundbeck; Lisdexamfetamine: Shire; Lurasidone: Servier; Brexpiprazole: Lundbeck; Treatment-Resistant Depression: LivaNova. He is founder of the Optimal Health Program, currently operating as Optimal Wellness. He is on the boards of both Mind Medicine Australia and The Mental health Foundation of Australia. He does not knowingly have stocks or shares in any pharmaceutical company.